Posted by Michael Wonder on 09 Dec 2021
FDA authorises new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals
8 December 2021 - Today, the U.S. FDA issued an emergency use authorization for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis of COVID-19 in certain adults and paediatric individuals (12 years of age and older weighing at least 40 kilograms).
The product is only authorised for those individuals who are not currently infected with the SARS-CoV-2 virus and who have not recently been exposed to an individual infected with SARS-CoV-2.
